Trials / Not Yet Recruiting
Not Yet RecruitingNCT05900089
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma. Around 7-18 patients will be subsequently enrolled into 3 different dose ascending cohorts. Additional 12-18 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0302 | SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2025-11-01
- Completion
- 2026-06-01
- First posted
- 2023-06-12
- Last updated
- 2023-06-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05900089. Inclusion in this directory is not an endorsement.